Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist

Journal of Clinical Investigation

Volumn 98, Issue 12, 1996, Pages 2729-2738

  Serradeil Le Gal, Claudine ^a   Lacour, Colette ^a   Valette, Gérard ^a   Garcia, Georges ^a   Foulon, Loïc ^a   Galindo, Gérard ^a   Bankir, Lise ^b   Pouzet, Brigitte ^b   Guillon, Gilles ^c   Barberis, Claude ^c   Chicot, Danielle ^c   Jard, Serge ^c   Vilain, Pol ^a   Garcia, Corine ^a   Marty, Eléonore ^a   Raufaste, Danielle ^a   Brossard, Gabrielle ^a   Nisato, Dino ^a   Maffrand, Jean Pierre ^a   Le Fur, Gérard ^a  

^a SANOFI   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

^c INSERM   (France)

Author keywords

aquaretic; nonpeptide antagonist; SR 121463A; V2 receptor; vasopressin

Indexed keywords

FUROSEMIDE; HYDROCHLOROTHIAZIDE; MOZAVAPTAN; N TERT BUTYL 4 [5' ETHOXY 4 (2 MORPHOLINOETHOXY) 2' OXOSPIRO[CYCLOHEXANE 1,3' INDOLE] 1' SULFONYL] 3 METHOXYBENZAMIDE; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR; VASOPRESSIN V2 RECEPTOR; VASOPRESSIN V2 RECEPTOR ANTAGONIST;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; POTASSIUM EXCRETION; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SODIUM EXCRETION; WATER RETENTION;

EID: 0009689526     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119098     Document Type: Article

References (58)

1. Morel, F., M. Imbert-Teboul, and D. Charbardes. 1987. Receptors to vasopressin and other hormones in the mammalian kidney. Kidney Int. 31:512-520.
2. Rouffignac, C. de, B. Corman, and N. Roinel. 1983. Stimulation by antidiuretic hormone of electrolyte tubular reabsorption in rat kidney. Am. J. Physiol. 244(Renal Fluid Electrolyte Physiol. 13):F156-F164.
3. Morel, A., A. O'Carroll, M.J. Brownstein, and S.J. Lolait. 1992. Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature (Lond.). 356:523-526.
4. Thibonnier, M., C. Auzan, Z. Madhun, P. Wilkins, L. Berti-Mattera, and E. Clauser. 1994. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J. Biol. Chem. 269(5): 3304-3310.
5. Sugimoto, T., M. Saito, S. Mochizuki , Y. Watanabe, S. Hashimoto, and H. Kawashima. 1994. Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J. Biol. Chem. 269(53):27088-27092.
6. De Keyzer, Y., C. Auzan, F. Lenne, C. Beldjord, M. Thibonnier, X. Bertagna, and E. Clauser. 1994. Cloning and characterization of the human V3 pituitary vasopressin receptor. FEBS (Fed. Eur. Biochem. Soc.) Lett. 356:215-220.
7. Lolait, S.J., A. M. O'Carroll, D.W. McBride, M. Konig, A. Morel, and M.J. Brownstein. 1992. Cloning and characterization of a vasopressin in V2 receptor and possible link to nephrogenic diabetes insipidus. Nature (Lond.). 357: 336-339.
8. Birnbaumer, M., A. Seibold, S. Gilbert, M. Ishido, C. Barberis, A. Antaramian, P. Bradet, and W. Rosenthal. 1992. Molecular cloning of the receptor for human antidiuretic hormone. Nature (Lond.). 357:333-335.
9. 2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. Eur. J. Biochem. 215:1-7.
10. Ufer, E., R. Postina, V. Gorbulev, F. Fahrenholz. 1995. An extracellular residue determines the agonist specificity of V2 vasopressin receptors. FEBS (Fed. Eur. Biochem. Soc.) Lett. 362:19-23.
11. Jard, S., J. Elands, A. Schmidt, and C. Barberis. 1988. Vasopressin and oxytocin receptors: an overview. In Progress in Endocrinology. H. Imura and K. Shizurne, editors. Excerpta Medica, Amsterdam. 1183-1188.
12. Burbach, J.P.H., A.H.A. Roger, S.J. Lolait, F.W. Van Leeuwen, E. Mezey, M. Palkovits, and C. Barberis. 1995. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family. Cell. Mol. Neurobiol. 15(5):573-595.
13. Rosenthal, X., A. Seibold, A. Antaramian, M. Lonergan, M.F. Arthus, G.N. Hendy, M. Birnbaumer, and D.G. Bichet. 1992. Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus. Nature (Lond.). 359:233-235.
14. Bichet, D.G., M. Lonergan, M.F. Arthus, T.M. Fujiwara, and K. Morgan. 1995. Nephrogenic diabetes insipidus due to mutations in AVPR2 and AQP2. In Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. T. Saito, K. Kurokawa, and S. Yoshida, editors. 605-613.
15. Laszlo, F.A., F. Laszlo, and D. De Wied. 1991. Pharmacology and clinical perspectives of vasopressin antagonists. Pharmacol. Rev. 43:73-108.
16. Mah, S.C., and K.G. Hofbauer. 1987. Antagonists of arginine-vasopressin: experimental and clinical applications. Drugs Future. 12:1055-1070.
17. Manning, M., and W.H. Sawyer. 1989. Discovery, development, and some uses of vasopressin and oxytocin antagonists. J. Lab. Clin. Med. 114:617-632.
18. Sorensen, J.B., M.K. Andersen, and H.H. Hansen. 1995. Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J. Int. Med. 238:97-110.
19. Goldsmith, S.R., D.L. Dodge-Brown, and A. Katz, 1989. α2-adrenergic stimulation and vasopressin in congestive heart failure. J. Cardiovasc. Pharmacol. 14:425-429.
20. Gavras, H. 1991. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin. Chem. 37/10(B):1828-1830.
21. Allison, N.L., C.R. Albrightson-Winslow, D.P. Brooks, F.L. Stassen, W.F. Huffman, R.M. Stote, and L.B. Kinter. 1988. Species heterogeneity and antidiuretic hormone antagonists: what are the predictors? In Vasopressin: Cellular and Integrative Functions, Allen W. Cowley, Jr., Jean-François Liard, and Dennis A. Ausiello, editors. Raven Press. Ltd., New York. 207-214.
22. Yamamura, Y., H. Ogawa, T. Chihara, K. Kondo, T. Onogawa, S. Nakamura, T. Mori, M. Tominaga, and Y. Yabuuchi. 1991. OPC-21268, an orally effective, nonpeptide vasopressin V1 receptor antagonist. Science (Wash. DC). 252:572-574.
23. Serradeil-Le Gal, C., J. Wagnon, C. Garcia, C. Lacour, P. Guiraudou, B. Christophe, G. Villanova, D. Nisato, J.P. Maffrand, G. Le Fur et al. 1993. Biochemical and pharmacological properties of SR 49059. a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J. Clin. Invest. 92: 224-231.
24. Yamamura, Y., H. Ogawa, H. Yamashita, T. Chihara, H. Miyamoto, S. Nakamura, T. Onogawa, T. Yamashita, T. Hosokawa, T. Mori, M. Tominaga, and Y. Yabuuchi. 1992. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br. J. Pharmacol. 105:787-791.
25. Ohnishi, A., Y. Orita, R. Okahara, H. Fujihara, T. Inoue, Y. Yamamura, Y. Yabuuchi, and T. Tanaka. 1993. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J. Clin. Invest. 92:2653-2659.
26. Ohnishi, A., Y. Orita, N. Takagi, T. Fujita, T. Toyoki, Y. Ihara, Y. Yamamura, T. Inoue, and T. Tanaka. 1995. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men. J. Pharmacol. Exp. Ther. 272:546-551.
27. Prous, J., N. Mealy, and J. Castañer. 1993. OPC-31260. Drugs Future. 18: 802-804.
28. Schmidt, A., S. Audigier, C. Barberis, S. Jard, M. Manning, A.S. Kolodziejezyk, and W.H. Sawyer. 1991. A radioiodinated linear vasopressin antagonist: a ligand with high affinity and specificity for V1A receptors. FEBS (Fed. Eur. Biochem. Soc.) Lett. 282:77-81.
29. Guillon, G., D. Butlen, B. Cantau, T. Barth, and S. Jard. 1982. Kinetic and pharmacological characterization of vasopressin membrane receptors from human kidney medulla: relation of adenylate cyclase activation. Eur. J. Pharmacol. 85:291-304.
30. Guillon, G., M. Trueba, D. Joubert, E. Grazzini, L. Chouinard, M. Coté, M. D. Payet, O. Manzoni, C. Barberis, M. Robert, and N. Gallo-Payet. 1995. Vasopressin stimulates steroid secretion in human adrenal glands:comparison with angiotensin-II effect. Endocrinology. 136:1285-1293.
31. Mouillac, B., B. Chini, M.N Balestre, J. Elands S. Trummp-Kallmeyer, J. Hoflack, M. Hibert, S. Jard, and C. Barberis. 1995. The binding site of neuropeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions. J. Biol. Chem. 270(43):25771-25777.
32. Stassen, F.L., R.W. Erickson, W.F. Huffman, J. Stefankiewicz, L. Sulat, and V.D. Wiebelhaus. 1982. Molecular mechanisms of novel antidiuretic antagonist: analysis of the effects on vasopressin binding and adenylate cyclase activation in animal and human kidney. J. Pharmacol. Exp. Ther. 223:50-54.
33. 2+ transport by rat liver plasma membranes vesicles. J. Biol. Chem. 259:1382-1385.
34. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254.
35. 1) and the concentration of inhibition which cause 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol. 22:3099-3108.
36. Munson, P.V. and D. Rodbard. 1980. Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem. 107: 229-239.
37. 3H]-SR 49059. Kidney Int. 50:499-505.
38. Valtin, H. 1992. Genetic models of diabetes insipidus. In Handbook of Physiology, section 8: Renal Physiology. E.E. Windhager, editor. Oxford University Press, New York. 1281-1315.
39. Tribollet, E., C. Barberis, J.J. Dreifuss, and S. Jard. 1988. Autoradiographic localization of vasopressin and oxytocin binding sites in rat kidney. Kidney Int. 33:959-965.
40. 2 receptor messenger ribonucleic acid in the liver and kidney of embryonic, developing and adult rats. Endocrinology. 133(3): 1849-1859.
41. Kinter, L.B., W.F. Huffman, and F.L. Stassen. 1988. Antagonists of the antidiuretic activity of vasopressin. Am. J. Physiol. 254(Renal Fluid Electrolyte Physiol. 23):F165-F177.
42. Kinter, L.B., B.E. Ilson, S. Caltabianol, D.K. Jorkasky, D.J. Murphy, H.A. Solleveld, G.R. Rhodes, D.P. Brooks, C.R. Algrightson-Winslow, R.M. Stote, and W.F. Huffman. 1991. Antidiuretic hormone antagonism in humans: are there predictors? In Vasopressin. S. Jard and R. Jamison, editors. Colloque INSERM/John Libbey Eurotext Ltd. 208:321-329.
43. Manning, M., W.H. Sawyer, and H. Design. 1993. Synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. J. Recept. Res. 13:195-214.
44. 3H]-SR 49059. a potent nonpeptide vasopressin V1a antagonist, to rat and human liver membranes. Biochem. Biophys. Res. Commun. 199:353-360.
45. Pettibone, D.J., T.M. Kishel, C.J. Woyden, B.V. Clineschmidt, M.G. Bock, R.M. Freidenger, D.F. Veber, and P.D. Williams. 1992. Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues. Life Sci. 50:1953-1958.
46. Williams, P.D., B.V. Clineschmidt, J.M. Erb, R.M. Freidinger, M.T. Guidotti, E.V. Lis, J.M. Pawluczyk, D.J. Pettibone, D.R. Reiss, D.F. Veber, and C.J. Woyden. 1995. 1-{1-[4-[(N-Acetyl-4-piperidmyl)oxy]-2-methoxybenzoyl]-piperidin-4-yl}-4H-3,1- benzoxazin-2(1H)-one (L-371,257): anew, orally bioavailable, nonpeptide oxytocin antagonist. J. Med. Chem. 38:4634-4636.
47. Liu, J.J., J.R. Chen, B.B. Buxton, C.I. Johnston, and L.M. Burrell. 1995. Potent inhibitory effect of SR 49059, an orally active nonpeptide vasopressin V1a receptor antagonist, on human arterial coronary bypass graft. Clin. Sci. 89: 481-485.
48. Bax, W.A., D. Nisato, E. Bos, and P.R. Saxena. 1994. The effect of novel nonpeptide receptor antagonists on arginine vasopressin-induced contractions of the human isolated coronary artery. Br. J. Pharmacol. 114(Prod. Suppl.):164.
49. Liard, J.F. 1992. cAMP and extrarenal vasopressin V2 receptors in dogs. Am. J. Physiol. 263 (Heart Circ. Physiol. 32):H1888-H1891.
50. Brinton, R.D., and E.A. Brownson. 1993. Vasopressin-induction of cyclic AMP in cultured hippocampal neurons. Dev. Brain Res. 71:101-105.
51. 2 receptor mRNA in rat hippocampus. Biochem. Biophys. Res. Commun. 205:1702-1706.
52. Fushimi, K., S. Uchida, Y. Hara, Y. Hirata, F. Marumo, and S. Sasaki. 1993. Cloning and expression of apical membrane water channel of rat kidney collecting tubule. Nature (Lond.). 361:549-552.
53. Nielsen, S., and M. Knepper. 1995. Vasopressin regulation of aquaporin 2 water channels in kidney collecting duct. In Neurohypophysis: Recent Progress in Vasopressin and Oxytocin Research. T. Saito, K. Urokawa, and S. Yoshida, editors. Elsevier Science B.V., Amsterdam, The Netherlands. 473-483.
54. Wathes, D.C., R.W. Swann, S.D. Birkett, D.G. Porter, and B.T. Pickering. 1983. Characterization of oxytocin, vasopressin, and neurophysin from the bovine corpus luteum. Endocrinology. 113:693-698.
55. Nicholson, H.D., 1983. More steroidogenic tissues containing oxytocin and vasopressin : human testis and fetal adrenal. Acta endocr. 103(suppl. 256): 243.
56. Ang, V.T., and J.S. Jenkins. 1984. Neurohypophysial hormones in the adrenal medulla. J. Clin. Endocrinol. Metab. 58:688-691.
57. Balment, R.J., M.J. Brimble, and M.L. Forsling. 1982. Oxytocin release and renal actions in normal and Brattleboro rats. Ann. NY Acad. Sci. USA. 394: 241-253.
58. Chou, C.L., S.R. DiGiovanni, A. Luther, S.J. Lolait, and M.A. Knepper. 1995. Oxytocin as an antidiuretic hormone II. Role of V2 vasopressin receptor. Am. J. Physiol. 269 (Renal Fluid Electrolyte Physiol. 38):F78-F85.